These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36708234)

  • 41. Structure-Activity Relationships, Deuteration, and Fluorination of Synthetic Cannabinoid Receptor Agonists Related to AKB48, 5F-AKB-48, and AFUBIATA.
    Sparkes E; Maloney CJ; Markham JW; Dane C; Boyd R; Gilchrist J; Moir M; Gordon R; Luo JL; Pike E; Walker KA; Kassiou M; McGregor IS; Kevin RC; Hibbs DE; Jorgensen WT; Banister SD; Cairns EA; Ametovski A
    ACS Chem Neurosci; 2024 Jun; 15(11):2160-2181. PubMed ID: 38766866
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Spicing it up - synthetic cannabinoid receptor agonists and psychosis - a systematic review.
    Hobbs M; Kalk NJ; Morrison PD; Stone JM
    Eur Neuropsychopharmacol; 2018 Dec; 28(12):1289-1304. PubMed ID: 30454908
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs.
    Gioé-Gallo C; Ortigueira S; Brea J; Raïch I; Azuaje J; Paleo MR; Majellaro M; Loza MI; Salas CO; García-Mera X; Navarro G; Sotelo E
    Biomed Pharmacother; 2023 Aug; 164():114934. PubMed ID: 37236027
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Do Toxic Synthetic Cannabinoid Receptor Agonists Have Signature in Vitro Activity Profiles? A Case Study of AMB-FUBINACA.
    Finlay DB; Manning JJ; Ibsen MS; Macdonald CE; Patel M; Javitch JA; Banister SD; Glass M
    ACS Chem Neurosci; 2019 Oct; 10(10):4350-4360. PubMed ID: 31513380
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthetic Cannabinoid-Related Deaths in England, 2012-2019.
    Yoganathan P; Claridge H; Chester L; Englund A; Kalk NJ; Copeland CS
    Cannabis Cannabinoid Res; 2022 Aug; 7(4):516-525. PubMed ID: 33998886
    [No Abstract]   [Full Text] [Related]  

  • 46. Interactions of endocannabinoid virodhamine and related analogs with human monoamine oxidase-A and -B.
    Pandey P; Chaurasiya ND; Tekwani BL; Doerksen RJ
    Biochem Pharmacol; 2018 Sep; 155():82-91. PubMed ID: 29958841
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11.
    Kevin RC; Cairns EA; Boyd R; Arnold JC; Bowen MT; McGregor IS; Banister SD
    Front Psychiatry; 2022; 13():1048836. PubMed ID: 36590635
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Linking in vitro and ex vivo CB
    Janssens LK; Hudson S; Wood DM; Wolfe C; Dargan PI; Stove CP
    Arch Toxicol; 2022 Nov; 96(11):2935-2945. PubMed ID: 35962200
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of Natural and Synthetic 1,4-naphthoquinones as Inhibitors of Monoamine Oxidase.
    Mostert S; Petzer A; Petzer JP
    Chem Biol Drug Des; 2016 May; 87(5):737-46. PubMed ID: 26684482
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of Monoamine Oxidase Activity in Alzheimer's Disease: An Insight into the Therapeutic Potential of Inhibitors.
    Behl T; Kaur D; Sehgal A; Singh S; Sharma N; Zengin G; Andronie-Cioara FL; Toma MM; Bungau S; Bumbu AG
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34207264
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Semicarbazones, thiosemicarbazone, thiazole and oxazole analogues as monoamine oxidase inhibitors: Synthesis, characterization, biological evaluation, molecular docking, and kinetic studies.
    Qazi SU; Naz A; Hameed A; Osra FA; Jalil S; Iqbal J; Shah SAA; Mirza AZ
    Bioorg Chem; 2021 Oct; 115():105209. PubMed ID: 34364054
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Privileged scaffolds as MAO inhibitors: Retrospect and prospects.
    Tripathi AC; Upadhyay S; Paliwal S; Saraf SK
    Eur J Med Chem; 2018 Feb; 145():445-497. PubMed ID: 29335210
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fourth generation of synthetic cannabinoid receptor agonists: a summary on the latest insights.
    Malaca S; Tini A; Umani Ronchi F
    Acta Biomed; 2022 Jan; 92(6):e2021546. PubMed ID: 35075053
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Monoamine oxidase-B inhibitors as potential neurotherapeutic agents: An overview and update.
    Tripathi RKP; Ayyannan SR
    Med Res Rev; 2019 Sep; 39(5):1603-1706. PubMed ID: 30604512
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Human Toxicity Caused by Indole and Indazole Carboxylate Synthetic Cannabinoid Receptor Agonists: From Horizon Scanning to Notification.
    Hill SL; Dunn M; Cano C; Harnor SJ; Hardcastle IR; Grundlingh J; Dargan PI; Wood DM; Tucker S; Bartram T; Thomas SHL
    Clin Chem; 2018 Feb; 64(2):346-354. PubMed ID: 29038156
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Selective Interactions of
    Chaurasiya ND; Midiwo J; Pandey P; Bwire RN; Doerksen RJ; Muhammad I; Tekwani BL
    Molecules; 2020 Nov; 25(22):. PubMed ID: 33212830
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Contribution of monoamine oxidase (MAO) to the binding of tertiary basic drugs in lung mitochondria.
    Yoshida H; Kamiya A; Okumura K; Hori R
    Pharm Res; 1989 Oct; 6(10):877-82. PubMed ID: 2608630
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of monoamine oxidase by selected phenylalkylcaffeine analogues.
    Petzer A; Grobler P; Bergh JJ; Petzer JP
    J Pharm Pharmacol; 2014 May; 66(5):677-87. PubMed ID: 24313346
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical Effects of Synthetic Cannabinoid Receptor Agonists Compared with Marijuana in Emergency Department Patients with Acute Drug Overdose.
    Zaurova M; Hoffman RS; Vlahov D; Manini AF
    J Med Toxicol; 2016 Dec; 12(4):335-340. PubMed ID: 27255136
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The impact of Australian legislative changes on synthetic cannabinoid exposures reported to the New South Wales Poisons Information Centre.
    Cairns R; Brown JA; Gunja N; Buckley NA
    Int J Drug Policy; 2017 May; 43():74-82. PubMed ID: 28343112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.